Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL5221758 | 1.00 | CYP1A2 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL18824897 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL3258 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL388561 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL388563 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL3259 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL995910 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL163442 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL163443 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI | |
| Histidine SCHEMBL8080341 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | KRANTZ ALEXANDER (US) | 2020-03-26 | — | — | US | disclosed |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | Krantz, Alexander (US) | 2019-06-25 | — | — | US | disclosed |
| EP-3413921-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | Krantz, Alexander (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20170275331-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | KRANTZ ALEXANDER (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2017139329-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABLES | KRANTZ ALEXANDER (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| US-20050245432-A1 | N-methyl amino acids | UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) | 2005-11-03 | — | — | US | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095275-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | MYCBP, FABP3, STUB1 | CYP1A2 3054/4885SLC7A5 955/4885CYP3A4 3090/4885 |
| US-20050245432-A1 | N-methyl amino acids | VIP, NPPA, PTMS | CYP1A2 4842/4885SLC7A5 101/4885CYP3A4 4773/4885 |
| US-20170275331-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF PROTEINS USING TRACELESS AFFINITY LABELS | MYCBP, FABP3, STUB1 | CYP1A2 3054/4885SLC7A5 955/4885CYP3A4 3090/4885 |
| US-10329321-B2 | Site-selective functionalization of proteins using traceless affinity labels | MYCBP, FABP3, STUB1 | CYP1A2 3054/4885SLC7A5 955/4885CYP3A4 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.